Predictors for Treatment Outcomes in Patients with Multi-drug Resistant Tuberculosis — China, 2018–2020

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Multi-drug resistant tuberculosis (MDR-TB) is a critical global public health problem. WHAT IS ADDED BY THIS REPORT? Sputum cultures and lung images show a strong association with treatment outcomes, serving as a multi-dimensional approach to identify MDR-TB p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shunxian, Qiu, Lei, Wu, Dingzhong, Zhang, Shaoyan, Pan, Chenhui, Li, Cui, Xiao, Heping, Huang, Fuli, Wang, Hua, Jiang, Feng, Zhang, Huiyong, Zheng, Peiyong, Lu, Zhenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681604/
https://www.ncbi.nlm.nih.gov/pubmed/36426288
http://dx.doi.org/10.46234/ccdcw2022.187
Descripción
Sumario:WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Multi-drug resistant tuberculosis (MDR-TB) is a critical global public health problem. WHAT IS ADDED BY THIS REPORT? Sputum cultures and lung images show a strong association with treatment outcomes, serving as a multi-dimensional approach to identify MDR-TB patients with poor outcomes. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? The results imply that funds and policy investments should be increased by early monitoring of MDR-TB patients, especially regarding imaging and sputum bacterium. By informing physicians on changes to the therapeutic schedule, treatment outcomes can be improved.

Ejemplares similares